Barbie just took a step forward for inclusivity and representation with the launch of a doll with type 1 diabetes.

Healthcare is transitioning to a patient-centric approach and healthcare consumerism. Patients have fast become consumers first, with the freedom to make decisions about their health journeys, and ...

Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange. That valued the newly independent company at CHF ...

GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

Discover how innovative approaches and specialised expertise in peptide API synthesis are increasing efficiency and driving advancements in the manufacturing of Active Pharmaceutical Ingredients ...

Common alpha-blocker prostate drugs linked to lower risk of dementia with Lewy bodies in large-scale observational study.

With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system ...

Despite the multiple challenges that faced clinical trials in 2023, according to GlobalData’s Pharmaceutical Intelligence Centre, some 22,338 studies were initiated. As we begin 2024, in the ...

Discover the transformative potential of digital health and AI in providing cutting-edge care for rare diseases like Lysosomal Storage Disorders (LSDs). Learn about the latest advancements and ...

The past two years have shone a spotlight on the UK life sciences industry. Pharma companies are now household names, having been thrust into the public’s consciousness after dominating the ...

Patient organisations have been celebrating the FDA approval yesterday of Amylyx' amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that ...

Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution ...